Hua-Jun He, Zhiyong He, Steven P Lund, Laure Turner, Yongjun Fan, Yu Qiu, David C Corney, Boro Dropulic, Rimas Orentas, Oxana Slessareva, Priscilla Welch, Katie Dungca, Ellen Stelloo, Gabrielle Dijksteel, Harma Feitsma, Sana Ahmed-Seghir, Rostyslav Makarenko, Engin Altunlu, Daniëlle Steenmans, Jan Spanholtz, Monica Raimo, Shai Senderovich, Barbara S Paugh, Chieh-Yuan Li, Benjamin Schroeder, Alexandra S Whale, Dilek Yener, Carole A Foy, Shareef Nahas, Feng Tu, Michael Sheldon, Yan Ding, Jennifer Kandell, Uma Lakshmipathy, Jennifer H McDaniel, Justin M Zook, Sierra Miller, Samantha Maragh, Simona Patange, Mahir Mohiuddin, Alessandro Tona, Kenneth D Cole, Sheng Lin-Gibson
{"title":"Interlaboratory assessment of candidate reference materials for lentiviral vector copy number and integration site measurements.","authors":"Hua-Jun He, Zhiyong He, Steven P Lund, Laure Turner, Yongjun Fan, Yu Qiu, David C Corney, Boro Dropulic, Rimas Orentas, Oxana Slessareva, Priscilla Welch, Katie Dungca, Ellen Stelloo, Gabrielle Dijksteel, Harma Feitsma, Sana Ahmed-Seghir, Rostyslav Makarenko, Engin Altunlu, Daniëlle Steenmans, Jan Spanholtz, Monica Raimo, Shai Senderovich, Barbara S Paugh, Chieh-Yuan Li, Benjamin Schroeder, Alexandra S Whale, Dilek Yener, Carole A Foy, Shareef Nahas, Feng Tu, Michael Sheldon, Yan Ding, Jennifer Kandell, Uma Lakshmipathy, Jennifer H McDaniel, Justin M Zook, Sierra Miller, Samantha Maragh, Simona Patange, Mahir Mohiuddin, Alessandro Tona, Kenneth D Cole, Sheng Lin-Gibson","doi":"10.1016/j.omtm.2025.101472","DOIUrl":null,"url":null,"abstract":"<p><p>While lentiviral vectors have played a critical role in the emergence of gene-modified cell therapies, safety concerns remain regarding potential insertional mutagenesis. Regulatory authorities strongly recommend risk assessment and management of vector copy numbers (VCNs), integration profiles, and integration sites in the lentivirus-based cell and gene therapy products. However, accurately measuring these parameters remains a significant challenge due to the lack of standardized methodologies and VCN reference materials (RMs). Toward this challenge, we conducted an interlaboratory study on NIST candidate RMs for VCN measurements. The candidate RMs comprise five human genomic DNA samples or fixed cells from clonal Jurkat cell lines with defined VCNs ranging from 0 to 4. All 12 study participants were able to identify the VCN in the five blinded samples using quantitative PCR (qPCR), digital PCR (dPCR), or next generation sequencing (NGS) assays. Consensus value of VCN and integration sites in these candidate RMs were achieved. The fixed clonal VCN cells were also used to evaluate an emerging imaging-based technology called molecular combing. This interlaboratory assessment demonstrated the utility, commutability, and suitability of the NIST VCN candidate RMs for quality assurance and improved confidence in VCN, integration profile, and integration site measurements.</p>","PeriodicalId":54333,"journal":{"name":"Molecular Therapy-Methods & Clinical Development","volume":"33 2","pages":"101472"},"PeriodicalIF":4.6000,"publicationDate":"2025-04-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12229725/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Molecular Therapy-Methods & Clinical Development","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1016/j.omtm.2025.101472","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/6/12 0:00:00","PubModel":"eCollection","JCR":"Q2","JCRName":"MEDICINE, RESEARCH & EXPERIMENTAL","Score":null,"Total":0}
引用次数: 0
Abstract
While lentiviral vectors have played a critical role in the emergence of gene-modified cell therapies, safety concerns remain regarding potential insertional mutagenesis. Regulatory authorities strongly recommend risk assessment and management of vector copy numbers (VCNs), integration profiles, and integration sites in the lentivirus-based cell and gene therapy products. However, accurately measuring these parameters remains a significant challenge due to the lack of standardized methodologies and VCN reference materials (RMs). Toward this challenge, we conducted an interlaboratory study on NIST candidate RMs for VCN measurements. The candidate RMs comprise five human genomic DNA samples or fixed cells from clonal Jurkat cell lines with defined VCNs ranging from 0 to 4. All 12 study participants were able to identify the VCN in the five blinded samples using quantitative PCR (qPCR), digital PCR (dPCR), or next generation sequencing (NGS) assays. Consensus value of VCN and integration sites in these candidate RMs were achieved. The fixed clonal VCN cells were also used to evaluate an emerging imaging-based technology called molecular combing. This interlaboratory assessment demonstrated the utility, commutability, and suitability of the NIST VCN candidate RMs for quality assurance and improved confidence in VCN, integration profile, and integration site measurements.
期刊介绍:
The aim of Molecular Therapy—Methods & Clinical Development is to build upon the success of Molecular Therapy in publishing important peer-reviewed methods and procedures, as well as translational advances in the broad array of fields under the molecular therapy umbrella.
Topics of particular interest within the journal''s scope include:
Gene vector engineering and production,
Methods for targeted genome editing and engineering,
Methods and technology development for cell reprogramming and directed differentiation of pluripotent cells,
Methods for gene and cell vector delivery,
Development of biomaterials and nanoparticles for applications in gene and cell therapy and regenerative medicine,
Analysis of gene and cell vector biodistribution and tracking,
Pharmacology/toxicology studies of new and next-generation vectors,
Methods for cell isolation, engineering, culture, expansion, and transplantation,
Cell processing, storage, and banking for therapeutic application,
Preclinical and QC/QA assay development,
Translational and clinical scale-up and Good Manufacturing procedures and process development,
Clinical protocol development,
Computational and bioinformatic methods for analysis, modeling, or visualization of biological data,
Negotiating the regulatory approval process and obtaining such approval for clinical trials.